Brilliant discussion of the SAFFRON trial by prof Leighl at #ESMO26!
As always, incredibly engaging, insightful and clinically focused!
Robust, clinically meaningful PFS and OS benefits with osimertinib + savolitinib.
Toxicity matters: edema, diarrhea and paronychia require careful management.
Key question: Is MET overexpression by IHC enough? IHC identifies eligible patients, but adding FISH can help avoid missing patients with MET amplification.
Precision oncology is not just about having the right drug, but also identifying the right patients! We have a clear new SOC here
#ESMOAmbassadors #ESMO26 #LungCancer #EGFR #MET